Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Directorate Change

21 Feb 2011 07:00

RNS Number : 5387B
Ultima Networks PLC
21 February 2011
 



21 February 2011

 

Ultima Networks plc

('Ultima' or the 'Company')

 

Appointment of Executive Director

 

The Board of Ultima is pleased to announce the appointment of Matteo Turi to its Board as an Executive Director of the Company with effect from 1 April 2011. Matteo will be responsible for the development of the Company's Green Power division and specifically for Ultima's solar power activities in Italy.

 

Matteo Turi (aged 39) is currently Finance Director at London-based RenGen Energy Group ("RenGen"), a renewable energy fund which sources, develops and finances renewable energy projects. RenGen's interests include equity and debt investments in renewable energy projects in Italy. Matteo joined RenGen in April 2008 where he has been, inter alia, responsible for all financial strategies and planning for RenGen's renewable energy investments. Matteo will initially continue to work with RenGen on a part-time basis.

 

Prior to joining RenGen, Matteo was European Financial Controller at K2 Partnering Solutions Ltd, a global provider of enterprise software consultants, from May 2007 to April 2008 where his role included business transformation and extensive change management. Previously Matteo was Divisional Financial Controller of Vanco plc, a Pan-European telecoms business, from May 1999 to March 2005 where he helped support the growth of Vanco during this period including the listing in 2001 of the company on the Official List of the London Stock Exchange. After leaving Vanco Matteo worked at International Poster Management, part of the Interpublic Group, as Divisional Financial Controller on a short term project and was Senior Overseas Financial Manager at Moneygram International Ltd where his role covered the integration of a major acquisition. Matteo has been a member of ACCA (the Association of Chartered Certified Accountants) since 2003.

 

Commenting on the board appointment, Prof. Humayun Mughal, the Company's Chairman and CEO, commented: "On behalf of the Board I would like to welcome Matteo onto the board and into his new role further strengthening our renewable energy capabilities. Matteo joins us with experience in the renewable energy sector at a time when we are looking to build upon our solar power credentials, particularly in Italy. We are confident that his experience will prove to be valuable to the growth of Ultima."

 

Matteo Turi is, or has been, a director of the following companies in the last 5 years:

 

Current Directorships/Partnerships:

 

Directorships/Partnerships within the last 5 years:

None

None

 

Matteo currently has no interest in the share capital of Ultima.

 

There are no further disclosures to be made in relation to Mr Matteo Turi under Schedule 2 (g) and rule 17 of the AIM Rules for Companies.

 

 

Ultima Networks plc

Prof. Humayun Mughal, Chairman and CEO

Tel: 01279 821 200

Allenby Capital Limited

(Nominated Adviser and Broker)

Tel: +44 (0)203 328 5656

Nick Naylor

Nick Athanas

Alex Price

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFMGZZMGVGMZZ
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.